Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer has signed a worldwide licensing agreement, excluding China, with biopharmaceutical company 3SBio to develop, manufacture and commercialise bispecific antibody targeting programmed cell ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese ...

Pfizer made a splashy entrance late Monday, revealing it is paying $1.25 billion upfront and committing up to $4.8 billion in milestones for ex-China rights to 3SBio’s SSGJ-707. Pfizer is ...

Pfizer Inc. PFE announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.‘s bispecific antibody SSGJ-707 in a deal potentially worth up to $6 billion.

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company tha ...

Pfizer's oncology pipeline, including the Seagen acquisition and positive trial results, is expected to fuel long-term revenue growth. Learn more on PFE stock here.

A big challenge for healthcare giant Pfizer (PFE 1.04%) is going to be replacing revenue from its COVID-19 vaccine this year and beyond. While it has a strong pipeline that can potentially help ...